DnB Asset Management
BEAM icon

DnB Asset Management’s Beam Therapeutics BEAM Stock Holding History

DnB Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,799
Closed -$510K – 733
2024
Q3 		$510K Buy
+20,799
New +$537K ﹤0.01% 660

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

DnB Asset Management's BEAM Position: Q4 2024 in Review

DnB Asset Management sold out of Beam Therapeutics (BEAM) in Q4 2024, closing a stake of 20,799 shares — an estimated $510K sold.

DnB Asset Management first reported a position in BEAM in Q3 2024 and held it in 1 quarter. The position peaked at $510K in Q3 2024. 231 funds tracked by Wall St. Rank hold BEAM as of Q4 2024.

  • DnB Asset Management reported no remaining Beam Therapeutics position as of Q4 2024 after selling out during the quarter.
  • DnB Asset Management sold 20,799 Beam Therapeutics shares in Q4 2024, an estimated $510K.
  • DnB Asset Management first reported a position in Beam Therapeutics in Q3 2024 and held it in 1 quarter.
  • DnB Asset Management's Beam Therapeutics position peaked at $510K in Q3 2024.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2024.

Based on DnB Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.